[PDF][PDF] 老年急性髓样白血病的治疗进展
陈璨， 黄永芬， 苗雨青 - 临床荟萃, 2023 - huicui.hebmu.edu.cn
急性髓样白血病(acutemyeloidleukemia, AML) 是一种血液系统恶性疾病, 其特征是髓系前体的
克隆性扩增, 在参与自我更新, 增殖和分化的过程中获得遗传异常. AML 在老年群体中发病率更 …
克隆性扩增, 在参与自我更新, 增殖和分化的过程中获得遗传异常. AML 在老年群体中发病率更 …
The Goldilocks dilemma in AML: Too young and fit, but not young and fit enough
ECS Martin, TY Zhang, GN Mannis - Clinical Lymphoma Myeloma and …, 2023 - Elsevier
Discussion It is well-described that increasing age—and in particular age greater than 60
years old—is a risk factor for poorer response to traditional intensive induction …
years old—is a risk factor for poorer response to traditional intensive induction …
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
K Usuki, T Miyamoto, T Yamauchi, K Ando… - International journal of …, 2024 - Springer
Abstract Objectives NS-87/CPX-351 is a dual-drug liposomal encapsulation of cytarabine
and daunorubicin. NS-87/CPX-351 exerts antileukemic action by maintaining a synergistic …
and daunorubicin. NS-87/CPX-351 exerts antileukemic action by maintaining a synergistic …
SOHO State of the Art Updates and Next Questions| An Update on Higher Risk Myelodysplastic Syndromes
MJ Hochman, AE DeZern - Clinical Lymphoma Myeloma and Leukemia, 2024 - Elsevier
High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of
clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions …
clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions …
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the …
F Klingler, WH Alsdorf, S Ghandili… - Leukemia & …, 2022 - Taylor & Francis
Recently new treatments for acute myeloid leukemia (AML) emerged, including regimens
like CPX-351 and cladribine with cytarabine and daunorubicin (DA+ C), demonstrating …
like CPX-351 and cladribine with cytarabine and daunorubicin (DA+ C), demonstrating …
Traitement des syndromes myélodysplasiques de bas risque
S Park - Bulletin du Cancer, 2023 - Elsevier
Résumé Dans les syndromes myélodysplasiques (SMD) de faible risque, l'objectif du
traitement est de corriger les cytopénies ou leurs conséquences. Les agents stimulant …
traitement est de corriger les cytopénies ou leurs conséquences. Les agents stimulant …
[HTML][HTML] 肿瘤治疗相关骨髓增生异常综合征和急性髓系白血病的临床特征及预后
徐旭升， 丁虹， 张昕， 廖益， 李赫， 刘钦瑜… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
肿瘤治疗相关骨髓增生异常综合征和急性髓系白血病的临床特征及预后- PMC Back to Top Skip
to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
[HTML][HTML] 成人急性髓系白血病靶向药物研究进展
刘真娇， 陈林 - Advances in Clinical Medicine, 2023 - hanspub.org
急性髓系白血病(acute myeloid leukemia, AML) 是成人中最常见的白血病, 其预后差, 生存期短,
具有高度异质性和显著的细胞遗传学特征. 近年来随着分子靶向及细胞生物学的发展 …
具有高度异质性和显著的细胞遗传学特征. 近年来随着分子靶向及细胞生物学的发展 …
How genetics can drive initial therapy choices for older patients with acute myeloid leukemia
JW Moore, N Torres, M Superdock, JH Mendler… - … treatment options in …, 2022 - Springer
Opinion statement Treatment of older adults with acute myeloid leukemia (AML) is
challenging. Therapy decisions must be guided by multiple factors including aging-related …
challenging. Therapy decisions must be guided by multiple factors including aging-related …
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN …
Accurate classification and risk stratification is critical for clinical decision making in AML
patients. In the newly proposed World Health Organization (WHO) and International …
patients. In the newly proposed World Health Organization (WHO) and International …